Coronary Perivascular Inflammation and Vascular Dysfunction: Mechanisms, Clinical Implications, and Evolving Management Strategies

Abstract

Coronary perivascular inflammation has emerged as a pivotal contributor to the pathogenesis of vascular dysfunction and atherosclerotic cardiovascular disease. This review synthesizes recent advances in the understanding of the mechanisms linking perivascular inflammation to coronary vascular dysfunction, highlights the epidemiological burden, and discusses risk factors, clinical features, diagnostic approaches, and current as well as emerging management strategies. Emphasis is placed on the translational relevance of mechanistic discoveries, the integration of novel imaging biomarkers, and the implications for personalized therapy in clinical practice.

Introduction

Coronary artery disease (CAD) remains the leading cause of morbidity and mortality worldwide. Beyond classical atherosclerotic mechanisms, perivascular inflammation has gained recognition as a critical driver of vascular dysfunction, contributing not only to plaque initiation and progression but also to adverse coronary events. Understanding the interplay between perivascular inflammation and vascular dysfunction is essential for the development of novel diagnostic and therapeutic strategies that target the underlying biology of CAD.

Epidemiology / Disease Burden

The global burden of CAD is substantial, with an estimated 17.9 million deaths annually attributable to cardiovascular diseases, of which CAD is the predominant contributor. Recent epidemiological studies utilizing advanced imaging modalities, such as positron emission tomography-computed tomography (PET-CT) and coronary computed tomography angiography (CCTA), have demonstrated a high prevalence of perivascular inflammation among patients with both stable and acute coronary syndromes. Notably, individuals with metabolic syndrome, diabetes mellitus, and chronic inflammatory disorders exhibit a heightened risk of perivascular inflammation, further compounding the overall disease burden.

Pathophysiology

The pathophysiological link between perivascular inflammation and vascular dysfunction is mediated through complex cellular and molecular mechanisms. Inflammation within the perivascular adipose tissue (PVAT) leads to the release of pro-inflammatory cytokines including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and monocyte chemoattractant protein-1 (MCP-1) which diffuse into the adjacent vascular wall. This paracrine signaling promotes endothelial dysfunction by reducing nitric oxide bioavailability, increasing oxidative stress, and facilitating leukocyte adhesion and transmigration. Over time, these processes accelerate vascular remodeling, intimal thickening, and the formation of vulnerable atherosclerotic plaques. Furthermore, perivascular inflammation has been implicated in the impairment of coronary flow reserve and the promotion of coronary microvascular dysfunction, both of which are associated with adverse cardiovascular outcomes.

Risk Factors

Traditional cardiovascular risk factors including hypertension, dyslipidemia, smoking, obesity, and diabetes mellitus are well-established contributors to perivascular inflammation. Additionally, emerging evidence points to the role of systemic inflammatory diseases (e.g., rheumatoid arthritis, psoriasis), chronic infections, and genetic predisposition in modulating the inflammatory milieu of the coronary vasculature. Lifestyle factors such as sedentary behavior, poor dietary habits, and chronic psychological stress also potentiate perivascular inflammation through neurohormonal and metabolic pathways.

Clinical Features

Coronary perivascular inflammation is often clinically silent until it manifests as acute coronary syndromes or exacerbates underlying vascular dysfunction. Patients may present with angina, exertional dyspnea, or symptoms of heart failure, particularly in the context of microvascular or endothelial dysfunction. In some cases, recurrent or refractory angina despite unobstructed epicardial coronary arteries may suggest a predominant role for inflammatory-mediated vascular dysfunction, underscoring the need for high clinical suspicion and targeted diagnostic evaluation.

Diagnosis

Advancements in non-invasive imaging have revolutionized the assessment of perivascular inflammation. CCTA-derived perivascular fat attenuation index (FAI) has emerged as a robust biomarker, with elevated FAI correlating with increased inflammatory activity and a higher risk of subsequent cardiac events. PET imaging using tracers such as 18F-fluorodeoxyglucose (FDG) and 68Ga-DOTATATE enables visualization of vascular and perivascular inflammation at the molecular level. Additionally, circulating biomarkers (e.g., high-sensitivity C-reactive protein, IL-6) and endothelial function testing (e.g., flow-mediated dilation) provide adjunctive information but lack the specificity of imaging-based approaches. Invasive techniques, such as coronary thermography and optical coherence tomography, may also detect inflammatory changes in selected clinical scenarios.

Treatment & Management

The management of coronary perivascular inflammation and associated vascular dysfunction is multifaceted, integrating lifestyle interventions, risk factor modification, and pharmacotherapy. Statins remain the cornerstone of therapy, exerting pleiotropic anti-inflammatory effects in addition to lipid-lowering. Emerging evidence supports the benefit of targeted anti-inflammatory therapies, such as interleukin-1β inhibitors (e.g., canakinumab) and colchicine, in reducing major adverse cardiovascular events among high-risk patients. Optimal glycemic control, blood pressure management, and smoking cessation are essential components of a comprehensive approach. In refractory cases or those with underlying systemic inflammation, immunomodulatory therapy may be warranted in collaboration with rheumatology or immunology specialists.

Recent Advances / Emerging Therapies

Recent advances in molecular imaging and precision medicine have paved the way for personalized risk stratification and targeted intervention. The use of CCTA-derived FAI is increasingly being incorporated into risk algorithms to guide intensity of anti-inflammatory and anti-atherosclerotic therapies. Novel agents targeting key inflammatory pathways including NLRP3 inflammasome inhibitors and monoclonal antibodies against pro-inflammatory cytokines are undergoing clinical investigation. Additionally, interventions aimed at modulating PVAT biology, such as angiotensin receptor-neprilysin inhibitors (ARNIs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors, have shown promise in preclinical and early clinical studies. The integration of omics-based approaches (e.g., transcriptomics, proteomics) holds potential for the identification of novel therapeutic targets and biomarkers.

Guideline Recommendations

Current international guidelines emphasize aggressive management of traditional cardiovascular risk factors in patients with evidence of coronary inflammation or vascular dysfunction. The 2021 ESC Guidelines on cardiovascular disease prevention advocate for the use of high-intensity statins, consideration of anti-inflammatory therapy in selected high-risk individuals, and the application of imaging-based risk assessment where available. The role of advanced imaging and novel anti-inflammatory agents is evolving, with ongoing studies likely to inform future guideline updates. Multidisciplinary collaboration is recommended for the management of patients with complex inflammatory phenotypes.

Conclusion

Coronary perivascular inflammation is a central mediator of vascular dysfunction and adverse cardiovascular outcomes. Advances in mechanistic understanding, imaging technologies, and targeted therapies are transforming the clinical approach to this entity. A comprehensive, guideline-driven strategy encompassing risk factor modification, pharmacologic intervention, and personalized care is essential to optimize outcomes in affected patients. Ongoing research will further clarify the pathobiology and therapeutic landscape, offering hope for improved prevention and management of coronary artery disease.